Private equity and strategic buyers approached for potential deal
Johnson & Johnson (J&J) is reportedly seeking to sell its Cerenovus stroke care business, valued between $1 billion and $1.5 billion, according to sources cited by Financial Times.
Key Insights:
- Cerenovus, founded in 2017, combines Pulsar Vascular, Neuravi, and parts of Codman Neuro after a $1 billion divestiture.
- The stroke care business focuses on neurovascular treatments and is based in Irvine, California.
- J&J MedTech, the second-largest medical device manufacturer globally, has reportedly approached private equity and strategic buyers for interest in Cerenovus.
- The move follows J&J’s unification of its MedTech brands in 2023, including Ethicon and DePuy Synthes.
J&J’s Cerenovus sale follows its $13.1 billion acquisition of Shockwave Medical in 2024, marking a shift in focus towards expanding its MedTech portfolio.
Follow MEDWIRE.AI for more updates on medical device industry shifts.
